Trevi Therapeutics Inc (OQ:TRVI)

Feb 06, 2024 06:30 am ET
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Corporate presentation will be held on Wednesday, February 14, 2024, at 10:00 a.m. ET
Jan 04, 2024 06:30 am ET
Trevi Therapeutics Provides Business Updates
NEW HAVEN, Conn., Jan. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a preview of business updates. Management will be attending the 13th Annual LifeSci Partners Corporate Access Event in San Francisco from January 8-10 and will be available to discuss updates. This event takes place during the week of the annual J.P. Morgan Health Care Confe
Dec 05, 2023 06:30 am ET
Nov 09, 2023 03:05 pm ET
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Initiated Phase 2a RIVER trial of Haduvio in refractory chronic cough (RCC) patients and expect topline data in the second half of 2024
Nov 02, 2023 07:30 am ET
Nov 01, 2023 04:05 pm ET
Oct 13, 2023 08:30 am ET
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis
Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment
Aug 01, 2023 07:30 am ET
Trevi Therapeutics to Participate in Upcoming August Events
NEW HAVEN, Conn., Aug. 1, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following events in August.
Jul 06, 2023 07:30 am ET
Trevi Therapeutics to Participate in Upcoming July Investor Events
NEW HAVEN, Conn., July 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following investor events in July.
May 30, 2023 07:30 am ET
Trevi Therapeutics to Participate in Upcoming June Conferences
Dr. Toby Maher will be presenting data results from the Phase 2 CANAL trial in IPF chronic cough at American Cough Conference
May 22, 2023 04:05 pm ET
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough
May 11, 2023 04:05 pm ET
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
 Initiating three clinical studies in chronic cough indications later this year
May 09, 2023 07:30 am ET
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023
Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m. EDT at the Yale School of Management
May 04, 2023 04:05 pm ET
May 02, 2023 07:30 am ET
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference
Dr. Toby Maher of the Keck School of Medicine will give oral presentations for both scientific abstracts on oral nalbuphine extended release for chronic cough in IPF
Apr 27, 2023 07:30 am ET
Apr 11, 2023 04:05 pm ET
Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Fireside chat will be held on Monday, April 17, 2023, at 11:00 a.m. ET
Mar 16, 2023 04:05 pm ET
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications
Mar 09, 2023 03:05 pm ET
Mar 08, 2023 06:30 am ET
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
NEW HAVEN, Conn., March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.  
Feb 21, 2023 07:00 am ET
Presenting on the Emerging Growth Conference on February 22 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 50th Emerging Growth Conference on February 22, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong...
Feb 16, 2023 06:30 am ET
Feb 02, 2023 06:30 am ET
Trevi Therapeutics to Present and Participate in Upcoming February Conferences
BIO CEO & Investor Conference, February 6-9 – Corporate presentation Tuesday, February 7, at 10:45 a.m. ET
Jan 25, 2023 09:00 am ET
Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 25, 2023) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with IPF, other chronic cough indications, and for the treatment of prurigo nodularis. President and CEO of the Company, Jennifer Good, joined Stock Day host Everett Jolly.
Jan 05, 2023 03:05 pm ET
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences
NEW HAVEN, Conn., Jan. 5, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced business updates.
Dec 19, 2022 03:05 pm ET
Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference
Biotech Showcase 2023, January 9-11 – Corporate presentation on Tuesday, January 10, at 3:00 p.m. PT
Nov 14, 2022 03:05 pm ET
Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer
David Clark, MD, MRCP, will lead the continued development of Haduvio™
Nov 10, 2022 03:05 pm ET
Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
Management to host a conference call and webcast today at 4:30 p.m. EDT
Nov 08, 2022 06:30 am ET
Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference
Fireside chat will be held on Wednesday, November 16, 2022, from 3:35 p.m. to 4:05 p.m. EDT
Nov 03, 2022 04:05 pm ET
Oct 27, 2022 07:30 am ET
Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting
Data from full set of subjects was statistically significant for the primary efficacy endpoint (p<0.0001)
Sep 23, 2022 01:18 am ET
/C O R R E C T I O N -- Trevi Therapeutics, Inc./
The news release "Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering", issued 22-Sept-2022 by Trevi Therapeutics, Inc. over PR Newswire was erroneously and prematurely issued by PR Newswire. The complete, corrected release follows:
Sep 22, 2022 08:00 pm ET
Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering
NEW HAVEN, Conn., Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo nodularis (PN), today announced the pricing of its underwritten public offering of [●] shares of its common stock at a public offering price of $[●] per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase [●] shares of common stock at a price
Sep 22, 2022 04:01 pm ET
Trevi Therapeutics Announces Proposed Public Offering
NEW HAVEN, Conn., Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo nodularis (PN), today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares and pre-funded warrants are being offered by Trevi. In addition, Trevi expects t
Sep 19, 2022 07:30 am ET
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Data from full set of subjects was statistically significant for the primary efficacy endpoint of daytime cough frequency reduction (p<0.0001)
Sep 07, 2022 07:30 am ET
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Presentation will be held on Monday, September 12, 2022, from 10:30 a.m. to 11:00 a.m. EDT
Aug 30, 2022 04:05 pm ET
Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022
The event will feature presentations from experts Dr. Peter Dicpinigaitis, MD, and Dr. Brian Kim, MD, MTR
Aug 24, 2022 07:30 am ET
Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release
Late-breaker abstract accepted for oral presentation on the interim analysis of cough in patients with idiopathic pulmonary fibrosis (IPF) at the upcoming European Respiratory Society International Congress 2022, Barcelona, Spain, September 4-6
Aug 22, 2022 09:30 am ET
Trevi Therapeutics, Inc. Discusses Commercialization for Its Investigational Therapy, Haduvio, with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - August 22, 2022) - The Stock Day Podcast welcomed Trevi Therapeutics, Inc. (NASDAQ: TRVI) ("the Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF). President and CEO of the Company, Jennifer Good, joined Stock Day host Sever Copley.
Aug 11, 2022 04:05 pm ET
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Reported positive results from the Phase 2b/3 PRISM trial of Haduvio™ in the treatment of Prurigo Nodularis
Aug 09, 2022 07:30 am ET
Trevi Therapeutics to Present at Upcoming August Conferences
NEW HAVEN, Conn., Aug. 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis (PN) and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced it will be presenting at the following investor and medical meeting conferences:
Aug 04, 2022 05:41 pm ET
Jun 29, 2022 07:30 am ET
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis
Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured by a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) (p=0.0157)
Jun 07, 2022 07:30 am ET
Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention
NEW HAVEN, Conn., June 7, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that Jennifer Good, President and CEO, will deliver a company presentation at 2022 BIO International Convention. In addition, Ms. Good will be participating in partnership meetings throughout the conference alongside Farrell Simon, SVP, Head of Commercial and Strategy. The 2022 BIO Internat
May 12, 2022 04:05 pm ET
Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update
Accelerated planning for next phase of development of Haduvio for the treatment of chronic cough in IPF based on results from statistically significant interim analysis of Phase 2 CANAL Trial
May 05, 2022 04:05 pm ET
May 03, 2022 07:30 am ET
Trevi Therapeutics to Present at Upcoming May Meetings
NEW HAVEN, Conn., May 3, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) for pruritus in prurigo nodularis (PN) and chronic cough in idiopathic pulmonary fibrosis (IPF), today announced that senior management will present at the following May meetings:
Apr 14, 2022 08:33 am ET
Thinking about buying stock in Clarus Therapeutics, Oncolytics Biotech, Mersana Therapeutics, Veru, or Trevi Therapeutics?
NEW YORK, April 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRXT, ONCY, MRSN, VERU, and TRVI.
Apr 11, 2022 08:00 am ET
Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference
UPDATE: Fireside chat will be held on Tuesday, April 12, 2022, from 10:15 a.m. to 10:55 a.m. EDT
Apr 07, 2022 08:00 am ET
Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market
Proceeds To Fund the Development of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis
Apr 05, 2022 04:25 pm ET
Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference
Fireside chat will be held on Tuesday, April 12, 2022, from 8:00 a.m. to 8:40 a.m. EDT
Mar 22, 2022 07:30 am ET
Mar 17, 2022 04:05 pm ET
Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update
Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistically Significant (p-value less than 0.0001)  Enrollment Ended Early
Mar 15, 2022 07:30 am ET
Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
Previously Announced Statistically Significant Interim Analysis Established Proof of Concept (p-value less than 0.0001)
Mar 09, 2022 03:05 pm ET
Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022
NEW HAVEN, Conn., March 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER). Today, Trevi announced that management will host a conference call and live audio webcast on Thursday, March 17, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the fourth quarter and full year ended December 31, 2021. 
Feb 24, 2022 06:30 am ET
Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
NEW HAVEN, Conn., Feb. 24, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF) suffering from chronic cough, establishing proof of concept. Further patient recruitment in the trial will stop based on the strength and consistency of the data.
Feb 01, 2022 06:30 am ET
Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN
NEW HAVEN, Conn., Feb. 1, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that it has completed enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) and expects to report top-line data in the second quarter of 2022.
Dec 16, 2021 03:05 pm ET
Trevi Therapeutics to Attend Multiple Conferences in January 2022
NEW HAVEN, Conn., Dec. 16, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that senior management will be participating in the 11th Annual LifeSci Partners Corporate Access Event taking place virtually from January 5-7, the Dermatology Summit taking place virtually on January 7, the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13 as well as the Biotech Showcase 2022 taking place v
Nov 15, 2021 06:30 am ET
Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
NEW HAVEN, Conn., Nov. 15, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will be presenting  at the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases taking place from November 16-18, 2021 in Boston, MA. Dr. Forbes' presentation on "Nalbuphine ER, an Oral Dual Acting Opioid Being Develop
Nov 10, 2021 03:05 pm ET
Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update
NEW HAVEN, Conn., Nov. 10, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2021, as well as provided business updates.
Nov 09, 2021 06:30 am ET
Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
NEW HAVEN, Conn., Nov. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that senior leadership members will participate in a virtual fireside chat, as well as host investor meetings, at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021. Participants include Jennifer Good, President and CEO, Lisa Delfini, CFO, and Bill Forbes, CDO. Trevi's present
Nov 03, 2021 04:05 pm ET
Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021
NEW HAVEN, Conn., Nov. 3, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Wednesday, November 10 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2021.
Oct 13, 2021 04:05 pm ET
Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)
NEW HAVEN, Conn., Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will present as part of a virtual viewpoint session at the 11th World Congress on Itch (WCI) taking place from October 22-23, 2021. The group viewpoint session will cover the topic "What I miss in itch research" where Dr. Forbes will discus
Oct 11, 2021 09:31 am ET
Thinking about buying stock in Adamas Pharmaceuticals, Trevi Therapeutics, Live Oak Acquisition, Comstock Resources, or Hallador Energy?
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADMS, TRVI, LOKB, CRK, and HNRG.
Oct 07, 2021 04:05 pm ET
Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference
NEW HAVEN, Conn., Oct. 7, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that senior management will be available for virtual one-on-one meetings at Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference taking place October 13, 2021.
Sep 30, 2021 06:57 pm ET
Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market
NEW HAVEN, Conn., Sept. 30, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that it has entered into a definitive agreement with a healthcare-focused institutional investor, for the purchase, in a private placement priced at-the-market under Nasdaq rules, of (i) 2,373,201 shares of common stock and accompanying warrants to purchase an aggregate of 4,746,402 shares o
Aug 12, 2021 04:05 pm ET
Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update
NEW HAVEN, Conn., Aug. 12, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended June 30, 2021, as well as business updates.
Aug 09, 2021 04:05 pm ET
Trevi Therapeutics Announces Additions to the Senior Leadership Team
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of Lisa Delfini, CPA, as Chief Financial Officer and Danine Summers, as Vice President, Medical Affairs. Ms. Delfini will lead the accounting and finance operations. Ms. Summers will be responsible for educating the medical community on Haduvio's data and development programs
Aug 05, 2021 04:05 pm ET
Trevi Therapeutics to Report Q2 2021 Financial Results on August 12
NEW HAVEN, Conn., Aug. 5, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Thursday, August 12 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2021.
Jun 09, 2021 07:30 am ET
Trevi Therapeutics to Present at 2021 BIO Digital Conference
NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Jennifer Good, President and CEO, has been selected to deliver a company presentation at 2021 BIO Digital. For 2021, the BIO International Convention will be held virtually as BIO Digital, on June 10 and 11 and from June 14-18.
Apr 07, 2021 07:30 am ET
Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Mar 25, 2021 04:05 pm ET
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results...
Mar 18, 2021 04:05 pm ET
Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Feb 18, 2021 04:05 pm ET
Trevi Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Feb 01, 2021 07:30 am ET
Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of...
Nov 11, 2020 04:05 pm ET
Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results...
Nov 10, 2020 07:30 am ET
Trevi Therapeutics to Present at Stifel Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Nov 04, 2020 04:05 pm ET
Trevi Therapeutics to Report Q3 2020 Financial Results on November 11
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Oct 21, 2020 08:00 am ET
Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today, announced updates to their...
Oct 13, 2020 04:05 pm ET
Trevi Therapeutics Announces the Hiring of Key Talent
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of...
Sep 09, 2020 04:05 pm ET
Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Aug 13, 2020 04:05 pm ET
Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results...
Aug 06, 2020 04:05 pm ET
Trevi Therapeutics to Report Q2 2020 Financial Results on August 13
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Aug 05, 2020 07:30 am ET
Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management...
Jul 13, 2020 07:30 am ET
Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the completion of...
Jun 30, 2020 04:45 pm ET
Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors
Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C....
Jun 17, 2020 04:05 pm ET
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present...
May 29, 2020 04:05 pm ET
Trevi Therapeutics to Hold Virtual 2020 Annual Meeting of Stockholders
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that, due to the public...
May 07, 2020 04:05 pm ET
Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Apr 08, 2020 04:05 pm ET
TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present...
Mar 16, 2020 08:00 am ET
TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Feb 20, 2020 04:05 pm ET
Trevi Therapeutics to Present at SVB Leerink Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present...
Feb 18, 2020 04:05 pm ET
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors
Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella,...
Nov 14, 2019 04:05 pm ET
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Nov 13, 2019 05:01 pm ET
Trevi Therapeutics to Present at Stifel Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will present...
Sep 05, 2019 04:05 pm ET
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Jennifer L. Good,...
Aug 12, 2019 04:05 pm ET
Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
Jun 18, 2019 04:05 pm ET
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Company management will...
Jun 13, 2019 04:09 pm ET
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the...
May 07, 2019 01:22 pm ET
Trevi Therapeutics Announces Pricing of Initial Public Offering
Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.